The director of the Center for Brain Health and Alzheimer prevention clinic at FAU medicine provides commentary about his time at the fourth annual International Congress on the Future of Neurology. [WATCH TIME: 4 minutes]
WATCH TIME: 4 minutes
“The questions were easily some of the best questions that I've received in the lectures that I've given over the last couple of years. The folks in the room really were there for one purpose, trying to learn more about the future.”
At the 2022 International Congress on the Future of Neurology (IFN) annual meeting, held September 23-24, in Manhattan, New York, Richard Isaacson, MD, director of the Center for Brain Health and Alzheimer Prevention Clinic at Florida Atlantic University medicine, served as a cochair. He also participated in a Medical Crossfire session on the topic of “Monoclonal Antibodies in AD: To Use or Not to Use” with Marwan N. Sabbagh, MD, FAAN, professor of neurology at the Barrow Neurological Institute.
Isaacson mentioned that the meeting comprised of a diverse group of people in neurology, allowing for collaborative conversations outside of his specialty of Alzheimer disease and dementia. In addition, he told NeurologyLive® that the people who attended this conference seek to learn more about the future of neurology and what it has in store for them, pondering on questions and engaging in conversation on paradigm changes.
Isascson noted that speakers discussed the concept of the progression of Alzheimer disease as a disease that occurs not only in the older population but in the younger population of adults. Currently, advanced technology has allowed biomarkers to assess symptoms earlier and prevent the progression of the disease. Isaacson explained that the field needs to think about biomarkers in the context of risk reduction within the development of an evidence-based plan of disease management.
In a recent conversation with NeurologyLive®, Isaacson spoke about his experience at IFN 2022. He also mentioned that treatment of neurological diseases is not a one-size-fits-all matter and that clinicians should approach it with a more of a personalized focus. Targeting therapies is the next era of precision medicine as people with different conditions are going to respond differently to different treatments.